EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old

Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez‐arnau, Jan Gutermuth, Emma Guttman‐yassky, Marcus Maurer, Graham Ogg, Peck Y. Ong, Liam O’mahony, Jürgen Schwarze, Amena Warner, Thomas Werfel, Oscar Palomares, Marek Jutel

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.
Original languageEnglish
JournalAllergy
Early online date29 Jul 2021
DOIs
Publication statusE-pub ahead of print - 29 Jul 2021

Fingerprint

Dive into the research topics of 'EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old'. Together they form a unique fingerprint.

Cite this